196 related articles for article (PubMed ID: 24659894)
21. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma.
Orvisky E; Drake SK; Martin BM; Abdel-Hamid M; Ressom HW; Varghese RS; An Y; Saha D; Hortin GL; Loffredo CA; Goldman R
Proteomics; 2006 May; 6(9):2895-902. PubMed ID: 16586431
[TBL] [Abstract][Full Text] [Related]
22. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry.
Zeng J; Yin P; Tan Y; Dong L; Hu C; Huang Q; Lu X; Wang H; Xu G
J Proteome Res; 2014 Jul; 13(7):3420-31. PubMed ID: 24853826
[TBL] [Abstract][Full Text] [Related]
23. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
[TBL] [Abstract][Full Text] [Related]
24. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis.
Wang N; Cao Y; Song W; He K; Li T; Wang J; Xu B; Si HY; Hu CJ; Li AL
J Gastroenterol Hepatol; 2014; 29(7):1544-50. PubMed ID: 24612022
[TBL] [Abstract][Full Text] [Related]
25. [Detection of Serum Peptides in Patients with Lung Squamous Cell Carcinoma by MALDI-TOF-MS and Analysis of Their Correlation with Chemotherapy Efficacy].
Zhao G; Xu B; Li X; Tang C; Qin H; Wang H; Yang S; Wang W; Gao H; He K; Liu X
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):318-325. PubMed ID: 28532539
[TBL] [Abstract][Full Text] [Related]
26. Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma.
An Y; Bekesova S; Edwards N; Goldman R
Dis Markers; 2010; 29(1):11-20. PubMed ID: 20826913
[TBL] [Abstract][Full Text] [Related]
27. Serum peptide profiling for potential biomarkers in early diagnosis of Escherichia coli bloodstream infection.
Ma Y; Chen C; Yang M; He S; Zhang K; Wang C
Cytokine; 2019 Aug; 120():71-77. PubMed ID: 31026733
[TBL] [Abstract][Full Text] [Related]
28. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
29. [The effects of different clinicopathologic variables on serum protein fingerprint in hepatocellular carcinoma patients].
Huang C; Fan J; Zhou J; Liu YK; Cui JF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):445-9. PubMed ID: 16772076
[TBL] [Abstract][Full Text] [Related]
30. [Study of serum proteome biomarkers with relation to the formation of portal vein tumor thrombi in hepatocellular carcinoma patients].
Huang C; Fan J; Zhou J; Liu YK; Cui JF; Kang XN; Yang PY; Tang ZY
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):781-5. PubMed ID: 15949388
[TBL] [Abstract][Full Text] [Related]
31. Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature.
Cao XL; Li H; Yu XL; Liang P; Dong BW; Fan J; Li M; Liu FY
PLoS One; 2013; 8(12):e82448. PubMed ID: 24349287
[TBL] [Abstract][Full Text] [Related]
32. SELDI-TOF MS Analysis of Hepatocellular Carcinoma in an Australian Cohort.
Schlichtemeier SM; Nahm CB; Xue A; Gill AJ; Smith RC; Hugh TJ
J Surg Res; 2019 Jun; 238():127-136. PubMed ID: 30771682
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.
Guo Y; Zhao J; Bi J; Wu Q; Wang X; Lai Q
J Hematol Oncol; 2012 Jul; 5():37. PubMed ID: 22760167
[TBL] [Abstract][Full Text] [Related]
34. Integrated peptide and glycan biomarker discovery using MALDI-TOF mass spectrometry.
Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R; Ressom HW
Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():3791-4. PubMed ID: 19163537
[TBL] [Abstract][Full Text] [Related]
35. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma.
Liu C; Shen J; Pan C; Yang L; Mou S; Wang H; Liang Y
Am J Clin Pathol; 2010 Aug; 134(2):235-41. PubMed ID: 20660326
[TBL] [Abstract][Full Text] [Related]
36. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
[TBL] [Abstract][Full Text] [Related]
37. Discovery and verification of urinary peptides in type 2 diabetes mellitus with kidney injury.
Fu G; Du Y; Chu L; Zhang M
Exp Biol Med (Maywood); 2016 Jun; 241(11):1186-94. PubMed ID: 26846977
[TBL] [Abstract][Full Text] [Related]
38. Identifying serum biomarkers for TACE therapy efficiency of hepatocellular carcinoma.
Li CY; Wang XL; Wang JH; Yan ZP; Gong GQ; Cheng JM; Chen Y; Liu LX; Li GP; Wang CG; Shi DH
Front Biosci (Elite Ed); 2011 Jan; 3(1):212-20. PubMed ID: 21196300
[TBL] [Abstract][Full Text] [Related]
39. Serum peptide profiles during progression of chronic hepatitis B virus infection to liver failure.
Han T; Liu H; Yu ZL; Li J; Wang L; Xiao SX; Li Y; Yu ML
J Viral Hepat; 2010 Mar; 17 Suppl 1():18-23. PubMed ID: 20586930
[TBL] [Abstract][Full Text] [Related]
40. Novel serum peptide model revealed by MALDI-TOF-MS and its diagnostic value in early bladder cancer.
Ding D; Chen M; Xiao X; Cao P; Li S
Int J Biol Markers; 2020 Sep; 35(3):59-66. PubMed ID: 32701013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
